• Molecular NamePhendimetrazine
  • Synonym(+)-3,4-Dimethyl-2-phenylmorpholine; (+)-phendimetrazine; (2S,3S)-3,4-Dimethyl-2-phenylmorpholine; 3-Phenyl-2-methylmorpholine; 3,4-Dimethyl-2-phenylmorpholine; d-2-Phenyl-3,4-dimethylmorpholine
  • Weight191.274
  • Drugbank_IDDB01579
  • ACS_NO634-03-7
  • Show 3D model
  • LogP (experiment)1.7
  • LogP (predicted, AB/LogP v2.0)2.29
  • pka7.6
  • LogD (pH=7, predicted)1.75
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.76
  • LogSw (predicted, AB/LogsW2.0)5.65
  • Sw (mg/ml) (predicted, ACD/Labs)7.88
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds1
  • TPSA12.47
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA stimulant drug of the morpholine chemical class used as an appetite suppressant.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic; Some of the drug is metabolized to Phenmetrazine and also Phendimetrazine-N-oxide.
  • Half life2~3 h
  • ExcretionUrinary elimination
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A